Progyny, Inc. (NASDAQ:PGNY) Holdings Raised by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH lifted its position in shares of Progyny, Inc. (NASDAQ:PGNY) by 90.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,467,780 shares of the company’s stock after acquiring an additional 695,740 shares during the period. Fort Washington Investment Advisors Inc. OH owned about 1.72% of Progyny worth $25,319,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in PGNY. Clear Harbor Asset Management LLC bought a new position in Progyny in the fourth quarter worth about $989,000. Ballentine Partners LLC acquired a new stake in shares of Progyny during the 4th quarter worth approximately $187,000. Leibman Financial Services Inc. lifted its holdings in shares of Progyny by 100.7% in the 4th quarter. Leibman Financial Services Inc. now owns 63,509 shares of the company’s stock worth $1,096,000 after purchasing an additional 31,872 shares during the last quarter. Nordea Investment Management AB boosted its position in Progyny by 5.8% during the 4th quarter. Nordea Investment Management AB now owns 185,042 shares of the company’s stock valued at $3,175,000 after purchasing an additional 10,203 shares during the period. Finally, Central Pacific Bank Trust Division grew its stake in Progyny by 89.8% during the 4th quarter. Central Pacific Bank Trust Division now owns 13,250 shares of the company’s stock worth $229,000 after buying an additional 6,270 shares during the last quarter. 94.93% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Chairman David J. Schlanger purchased 150,000 shares of the stock in a transaction on Thursday, December 26th. The shares were bought at an average price of $14.68 per share, for a total transaction of $2,202,000.00. Following the completion of the acquisition, the chairman now directly owns 228,269 shares in the company, valued at approximately $3,350,988.92. This trade represents a 191.65 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Peter Anevski purchased 209,500 shares of the company’s stock in a transaction dated Monday, December 23rd. The stock was purchased at an average cost of $14.48 per share, for a total transaction of $3,033,560.00. Following the transaction, the chief executive officer now owns 441,463 shares of the company’s stock, valued at approximately $6,392,384.24. This trade represents a 90.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 12.30% of the company’s stock.

Progyny Stock Performance

Shares of NASDAQ PGNY opened at $21.15 on Thursday. The business has a 50 day simple moving average of $16.40 and a 200 day simple moving average of $19.43. Progyny, Inc. has a 52 week low of $13.39 and a 52 week high of $42.08. The stock has a market cap of $1.80 billion, a price-to-earnings ratio of 36.47, a PEG ratio of 2.10 and a beta of 1.31.

Progyny (NASDAQ:PGNY) last posted its earnings results on Tuesday, November 12th. The company reported $0.11 EPS for the quarter, missing the consensus estimate of $0.37 by ($0.26). The business had revenue of $286.63 million during the quarter, compared to the consensus estimate of $296.85 million. Progyny had a return on equity of 11.36% and a net margin of 5.03%. The business’s revenue was up 2.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.16 earnings per share. On average, analysts predict that Progyny, Inc. will post 0.6 EPS for the current year.

Wall Street Analysts Forecast Growth

PGNY has been the subject of several analyst reports. JPMorgan Chase & Co. reissued a “neutral” rating and set a $17.00 price target (down previously from $22.00) on shares of Progyny in a report on Monday, December 2nd. Barclays decreased their target price on shares of Progyny from $30.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. Truist Financial reaffirmed a “hold” rating and set a $19.00 price target (down previously from $26.00) on shares of Progyny in a report on Wednesday, November 13th. Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price objective on shares of Progyny in a research report on Tuesday, October 1st. Finally, Canaccord Genuity Group lowered their target price on Progyny from $18.00 to $17.00 and set a “hold” rating on the stock in a research report on Wednesday, November 13th. Nine equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $25.00.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.